Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 25HR+/HER2- Advanced Breast Cancer 3Breast Cancer Metastatic 3Squamous Cell Carcinoma of Head and Neck 2Ovarian Neoplasms 2Esophageal Squamous Cell Carcinoma 2Advanced Breast Cancer 2Triple Negative Breast Neoplasms 1Solid Tumor 1HR Positive HER2 Negative Advanced Breast Cancer 1HER2-positive Breast Cancer 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasm Female 1Brain Neoplasms 1Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed 1

Interventions

Fluorodeoxyglucose F18 7Irinotecan 4Fluorouracil 4Cyclophosphamide 4Bevacizumab 4toripalimab 3pembrolizumab 3olaparib 3Radiosurgery 3Cisplatin 3Capecitabine 3vistusertib 2tislelizumab 2spartalizumab 2fludarabine 2atezolizumab 2apatinib 2Temozolomide 2Technetium 2Specimen Handling 2Sirolimus 2Radiotherapy 2Proton Therapy 2Paclitaxel 2Leucovorin 2Letrozole 2Hydroxychloroquine 2Everolimus 2Drug Therapy 2Docetaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Solid Tumor × dalpiciclib × Clear all
NCT05512780 2022-08-23

Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage â…¡-â…¢ HR-positive/HER2-negative Breast Cancer

Hebei Medical University Fourth Hospital

Phase 2 Unknown
30 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡